Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery

Brief summary (registry, in English)

This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (CA 19-9 levels \<500, no vessel contact and recommended by multidisciplinary tumor board). ctDNA positive patients are randomized to either receive neoadjvuant chemotherapy at current gold standard physicians choice vs. upfront surgery because of assumed high biological risk for early recurrence of ctDNA+. ctDNA- will receive upfront surgery in adherence to local guidelines.

What you commit to

• Study type: Interventional · Phase 2
• Planned participants: 100
• From 11 Jan 2024 to the primary completion date, 1 Jun 2026
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.